Surmodics to Present at Upcoming Investor Conferences

May 22, 2017 at 8:00 AM EDT

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--May 22, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and information systems and chief financial officer, will be attending two upcoming investor conferences.

On Wednesday, May 24, 2017, at 12:30 p.m. PT (2:30 p.m. CT), company management will make a presentation at the B. Riley 2017 Institutional Investors Conference in Santa Monica, California.

On Tuesday, June 6, 2017, at 1:30 p.m. ET (12:30 p.m. CT), company management will make a presentation at the Jefferies Healthcare Conference in New York City.

Live audio webcasts of the presentations can be accessed by going to the investor relations portion of the Company’s website at and clicking on the webcast icon. Webcasts will be archived on the Company’s website for 90 days.

About Surmodics, Inc.

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays. Following two recent acquisitions of Creagh Medical and NorMedix, the Company is executing a key growth strategy for its medical device business by expanding to offer total intravascular product solutions to its medical device customers. The combination of proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities, enables Surmodics to significantly increase the value it offers with highly differentiated intravascular solutions designed and engineered to meet the most demanding requirements. With this focus on offering total solutions, Surmodics’ mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information about the company, visit The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.

Source: Surmodics, Inc.

Surmodics, Inc.
Andy LaFrence, 952-500-7000